Apoptosis induced FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases

被引:47
作者
Mitsiades, N
Poulaki, V
Mitsiades, CS
Koutras, DA
Chrousos, GR
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA USA
[3] Univ Athens, Sch Med, GR-11527 Athens, Greece
[4] NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S1043-2760(01)00441-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
FasL and TRAIL/Apo2L participate in cell-mediated cytotoxicity by inducing apoptosis in susceptible cells via respective cell surface receptors. Normal and neoplastic thyroid tissues are resistant-to FasL-induced apoptosis but are sensitized by Th-1-type cytokines. In Hashimoto's thyroiditis, both FasL and its receptor, Fas, are strongly upregulated and their interaction leads to the suicidal/fratricidal death of thyrocytes. In Graves' disease, FasL expression in thyroid follicular cells is induced by thionamides and kills infiltrating lymphocytes. In this condition, Th-2-type cytokines upregulate the anti-apoptotic molecules FLIP and Bcl-x(L) and protect thyrocytes from apoptosis. FasL is expressed by neoplastic thyrocytes and induces apoptosis of infiltrating lymphocytes. TRAIL/Apo2L kills thyroid carcinoma cells but spares normal thyrocytes,thus providing a potential therapy for thyroid cancer.
引用
收藏
页码:384 / 390
页数:7
相关论文
共 62 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]   TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention [J].
Ahmad, M ;
Shi, YF .
ONCOGENE, 2000, 19 (30) :3363-3371
[3]   Fas (CD95) expression is up-regulated on papillary thyroid carcinoma [J].
Arscott, PL ;
Stokes, T ;
Myc, A ;
Giordano, TJ ;
Thompson, NW ;
Baker, JR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :4246-4252
[4]   Apoptosis and thyroiditis [J].
Arscott, PL ;
Baker, JR .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1998, 87 (03) :207-217
[5]   Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor [J].
Arscott, PL ;
Knapp, J ;
Rymaszewski, M ;
Bartron, JL ;
Bretz, JD ;
Thompson, NW ;
Baker, JR .
ENDOCRINOLOGY, 1997, 138 (11) :5019-5027
[6]   Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[7]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[8]   Editorial: Dying (apoptosing?) for a consensus on the fas death pathway in the thyroid [J].
Baker, JR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (08) :2593-2595
[9]   THE IMMUNE-RESPONSE TO PAPILLARY THYROID-CANCER [J].
BAKER, JR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (12) :3419-3420
[10]   Specificity questions concerning the clone 33 anti-fas ligand antibody [J].
Baker, JR ;
Bretz, JD .
CELL DEATH AND DIFFERENTIATION, 2000, 7 (01) :8-9